CSI Market
Sign In | Register

Transcode Therapeutics Inc (RNAZ) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RNAZ Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Transcode Therapeutics Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-50.91
Depreciation & amortization0.05
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.06
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-0.16
Embedded Derivative Gain Loss On Embedded Derivative Net-
Increase Decrease In Accounts Payable And Accrued Liabilities Excluding Increase Decrease In Interest Payable Net1.77
Warrant Issuance Costs Private Investment In Public Entity-
Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities-
Deemed Dividend Arising From Warrant Modification-
Operating Lease Right Of Use Asset Amortization Expense-
Change In Fair Value Of Contingent Consideration-0.12
Increase Decrease In Deferred Tax Liabilities0.23
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Accounts Payable0.00
Increase (Decrease) in Interest Payable, Net0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.34
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities39.24
Discontinued operations0.00
Net Cash flow from Operating Activities-10.38
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.95
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits Outstanding0.00
Other financing activities net0.00
Other net0.00
Proceeds From Subscription Receivable-
Proceeds From Escrow Deposits Applied To Exercise Of Warrants-
Paymentsofdeferredofferingcostsadditional-
Payments Of Deferred Offering Cost Additional-
Payment Of Deferred Offering Costs-
Payments Of Deferred Offering Cost-
Payments Of Deferred Offering Costs Additional-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.95
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-10.38
Total Cash Flow-9.43
4 historic quarters locked

Sign in to unlock the full Transcode Therapeutics Inc cash flow history.

Sign In Create Free Account

About Transcode Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001829635-26-000003

Figures are derived from filed reports and may be restated. Historical data is subject to revision.